Deutsche Bank AG Grows Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Deutsche Bank AG increased its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 50.7% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 133,886 shares of the company's stock after acquiring an additional 45,066 shares during the quarter. Deutsche Bank AG's holdings in Amneal Pharmaceuticals were worth $1,060,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in AMRX. Barclays PLC raised its position in shares of Amneal Pharmaceuticals by 134.1% during the 3rd quarter. Barclays PLC now owns 296,384 shares of the company's stock worth $2,466,000 after purchasing an additional 169,756 shares during the last quarter. SG Americas Securities LLC raised its holdings in Amneal Pharmaceuticals by 16.7% in the 4th quarter. SG Americas Securities LLC now owns 74,518 shares of the company's stock valued at $590,000 after acquiring an additional 10,674 shares during the last quarter. Janney Montgomery Scott LLC acquired a new position in Amneal Pharmaceuticals during the fourth quarter worth $121,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management increased its position in Amneal Pharmaceuticals by 13.6% during the fourth quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 46,240 shares of the company's stock worth $366,000 after purchasing an additional 5,523 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. purchased a new stake in Amneal Pharmaceuticals in the fourth quarter valued at $520,000. Hedge funds and other institutional investors own 31.82% of the company's stock.

Insider Buying and Selling

In other Amneal Pharmaceuticals news, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of Amneal Pharmaceuticals stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $8.35, for a total value of $41,750,000.00. Following the completion of the sale, the insider now owns 48,578,209 shares in the company, valued at $405,628,045.15. The trade was a 9.33% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Gautam Patel sold 80,000 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $8.90, for a total transaction of $712,000.00. Following the completion of the sale, the director now directly owns 1,808,886 shares in the company, valued at $16,099,085.40. This represents a 4.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. 17.45% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research analysts have recently commented on AMRX shares. Barclays raised their price objective on shares of Amneal Pharmaceuticals from $10.00 to $11.00 and gave the company an "overweight" rating in a research note on Monday, March 3rd. Wall Street Zen lowered Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Tuesday, May 13th. Finally, JPMorgan Chase & Co. upgraded shares of Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and upped their price target for the company from $9.00 to $12.00 in a research report on Monday, February 24th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $11.50.

Amneal Pharmaceuticals Stock Performance

NASDAQ AMRX traded down $0.02 during trading hours on Friday, reaching $7.29. The company's stock had a trading volume of 116,378 shares, compared to its average volume of 1,437,519. The company's 50-day moving average is $7.50 and its two-hundred day moving average is $8.01. Amneal Pharmaceuticals, Inc. has a fifty-two week low of $6.29 and a fifty-two week high of $9.48. The stock has a market cap of $2.28 billion, a PE ratio of -10.71 and a beta of 1.17.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last released its quarterly earnings results on Friday, May 2nd. The company reported $0.19 EPS for the quarter, beating the consensus estimate of $0.14 by $0.05. Amneal Pharmaceuticals had a negative net margin of 6.88% and a negative return on equity of 346.26%. The business had revenue of $695.42 million for the quarter, compared to analyst estimates of $714.78 million. Equities analysts expect that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current fiscal year.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.